MRSN | Mersana Therapeutics, Inc.
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanaâs second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanaâs customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companyâs early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companyâs Immunosynthen platform. In addition, multiple partners are using Mersanaâs Dolaflexin platform to advance their ADC pipelines.
840 Memorial Drive
Key Persons / Board of Directors
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.